Assorted news from the last week: Children with birth defects who were conceived via in vitro fertilization (IVF) were more likely to develop childhood cancer compared to those conceived naturally, according to the results of a cohort study originating at Michigan State University. The likelihood of cancer survivors developing a new, unrelated malignancy is “about 10 to 20 percent higher” than someone in the general population. The insurance dropout rate among adolescents and young adult cancer survivors may have been lowered due to the dependent coverage provision in the Affordable Care Act, according to the findings of a new study […]
Read moreCurrently browsing: Community News
CC Community News Digest (October 19-25)
Assorted news from the last week: The International Cancer Research Partnership (ICRP) published results from its Impact of Covid-19 on childhood cancer research funding organizations survey More news about the effect of Covid-19 on cancer research (all types, not just pediatric and AYA). A team of scientists at Texas A&M University have developed a way to more accurately both detect and monitor a common type of pediatric brain cancer, setting the stage for giving clinicians a real-time view into how the cancer responds to treatment. Researchers at the University of Michigan have demonstrated that a new liquid biopsy approach overcomes traditional barriers to [...] Read more
CC Community News Digest (October 12-18)
Assorted news from the last week: This year’s Cancer Grand Challenges (funded by Cancer Research UK and the National Cancer Institute) include a category for Solid Tumors in Children. Contract Research Organization PRA Health Sciences published a white paper encouraging industry sponsors to identify, seek out, and partner with patient organizations as they try to meet the demands of the RACE for Children Act. OncoHeroes BioSciences announced that its therapeutic Volasertib received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) to treat pediatric rhabdomyosarcoma and other rare soft tissue sarcomas. Cooking up Change launched this video and a […]
Read moreCC Community News Digest (October 5-11)
Assorted news from the last week: Researchers at Baylor College of Medicine and the University of North Carolina at Chapel Hill have genetically modified human NKT cells with a chimeric antigen receptor (CAR) that enables them to specifically recognize and attack neuroblastoma, a form of childhood cancer. In a recent Journal of Clinical Oncology article, members from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans (iPSP) and pediatric investigation plans (PIP) with regulatory authorities in order to facilitate pediatric cancer drug […]
Read moreCC Community News Digest (week of September 28-October 4)
Assorted news from the last week: Twenty percent of children treated with drugs called anthracyclines go on to suffer heart failure later in life. Dr. Greg Aune explores why. Research to develop a new treatment and bring a new drug to market is extremely expensive, and conventional methods for obtaining funding aren’t adequate. New funding models can help disease-focused nonprofit research foundations play a central role in raising capital and mobilizing an ecosystem focused on controlling and curing a disease. The U.S. Senate unanimously passed S.Res.742 – A Senate Resolution designating September as National Childhood Cancer Awareness Month. Senators Manchin […]
Read moreCC Community News Digest (week of September 21-27)
Assorted news from the last week: In a Swedish study of how families in pediatric oncology experienced illness‐related information and communication with professionals and within the family, eighty‐six percent of the parents and 71% of the siblings reported that they had not received enough or any information about how the cancer and its treatment could affect the child's psychological health. EMA has published the final version of ‘Preparedness of medicines’ clinical trials in paediatrics - recommendations by the Enpr-EMA working group on trial preparedness.' Key takeaways: The definition of “trial preparedness” has been extended and a new term “trial feasibility” has [...] Read more
Childhood Cancer: Cross-Sector Strategies for Prevention Report Released
Some CAC2 Members have spent months working on the Childhood Cancer Prevention Initiatives with a wider community of folks dedicated to working on childhood cancer prevention. Click the image to access the report and more! Below they have shared links to social media content and videos for the report. Link to the Social Media Toolkit Links to the Childhood Cancer Prevention video: Please like the video on Instagram, and crosspost/share on Facebook and Twitter Link to the ASBC Facebook Live recording of the 9/23 teleconference: https://www.facebook.com/watch/?v=404729213871394&extid=dJ3sJFYFmcI6f5mB Media Folder Click here to view the folder with all of the social media images. Spanish will be added soon! Link to the [...] Read more
CC Community News Digest (week of September 14-20)
Assorted news from the last week: A study by a French research team found “that treatment with growth hormones is not associated with an increased risk of second tumors” for children who survived cancer and later received treatment for growth hormone deficiency. Brigitte Widemann, chief of the Pediatric Oncology Branch for the Center for Cancer Research at the National Cancer Institute, started conducting clinical trials for neurofibromatosis type 1 (NF1) in 2001, and results from the most recent trial holds promise to shrink the tumors or stop their growth. FDA grants rare pediatric disease designation to a second CAR (chimeric [...] Read more
CC Community News Digest (week of September 7-13)
Assorted news from the last week: Camp Okizu at Berry Creek, a camp for pediatric cancer patients and their families, sustained significant damage in California's Bear Fire. Early results of a clinical trial show that for children and adults with advanced soft tissue sarcoma, adding the targeted drug pazopanib (Votrient) to chemotherapy and radiation treatment is safe and increases the chances that most of the tumor will be dead before surgery. Study in Pediatric Blood Cancer concludes that physicians can foster trust through patient-centered communication and provision of high-quality information about a child’s cancer. Baltimore Ravens honor pediatric cancer patients. [...] Read more
Guest Blog–September 9 Virtual Day of Action: How to Get Involved
By Guest Blogger Sarah Milberg, Co-Chair of the Alliance for Childhood Cancer and Director of Government Relations and Advocacy for the St. Baldrick’s Foundation Today is the day! The childhood cancer community is joining together today to use our collective voice to build support for funding for the Childhood Cancer STAR Act, the most comprehensive childhood cancer bill ever. Advocates across the childhood cancer community are writing to their members of Congress, posting on social media, and spreading the word to their networks about today’s Virtual Day of Action. If your organization would like to participate, please use these materials so [...] Read more